Based on the Sanofi ADR stock forecast from 1 analysts, the average analyst target price for Sanofi ADR is USD 57.50 over the next 12 months. Sanofi ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Sanofi ADR is Bullish , which is based on 11 positive signals and 3 negative signals. At the last closing, Sanofi ADR’s stock price was USD 47.71. Sanofi ADR’s stock price has changed by +1.94% over the past week, -0.56% over the past month and -2.53% over the last year.
No recent analyst target price found for Sanofi ADR
No recent average analyst rating found for Sanofi ADR
Company Overview Sanofi ADR
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France. Read Less
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides...Read More
Frequently Asked Questions About Sanofi ADR (SNY) Stock
Based on ratings from 1 analysts Sanofi ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 2 buy, sell and hold ratings.
SNY stock's dividend yield is 4.27%.
Our analysis grades SNY stock's dividend yield at A+. This means that SNY stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this SNY may be a good dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for SNY is USD 57.50 over the next 12 months. The maximum analyst target price is USD 60 while the minimum anlayst target price is USD 55.
SNY stock's Price/Earning ratio is 25.24.
Our analysis grades SNY stock's Price / Earning ratio at B. This means that SNY stock's Price/Earning ratio is above 14% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this SNY may be undervalued for its sector.
The last closing price of SNY's stock was USD 47.71.
The most recent market capitalization for SNY is USD 119.62B.
Based on targets from 1 analysts, the average taret price for SNY is projected at USD 57.50 over the next 12 months.
This means that SNY's stock price may go up by +20.52% over the next 12 months.
We can't find any ETFs which contains Sanofi ADR's stock.
As per our most recent records Sanofi ADR has 86,088 Employees.
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Frequently Asked Questions About Sanofi ADR (SNY) Stock
Based on ratings from 1 analysts Sanofi ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 2 buy, sell and hold ratings.
SNY stock's dividend yield is 4.27%.
Our analysis grades SNY stock's dividend yield at A+. This means that SNY stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this SNY may be a good dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for SNY is USD 57.50 over the next 12 months. The maximum analyst target price is USD 60 while the minimum anlayst target price is USD 55.
SNY stock's Price/Earning ratio is 25.24.
Our analysis grades SNY stock's Price / Earning ratio at B. This means that SNY stock's Price/Earning ratio is above 14% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this SNY may be undervalued for its sector.
The last closing price of SNY's stock was USD 47.71.
The most recent market capitalization for SNY is USD 119.62B.
Based on targets from 1 analysts, the average taret price for SNY is projected at USD 57.50 over the next 12 months.
This means that SNY's stock price may go up by +20.52% over the next 12 months.
We can't find any ETFs which contains Sanofi ADR's stock.
As per our most recent records Sanofi ADR has 86,088 Employees.
